# SMC<sup>™</sup> : an alternative to other technologies for development of immunogenicity assay for cytokines ADA

EIP Lisbon– 17-19 February 2020 Eric Guillemare

SANOFI 🌍


Translational Medicine and Early Development Biomarkers & Clinical Bioanalysis

# **ADA Assay method : classical bridging format**

Classical format : bridged complex ADA-Drug in solution Drug labeled with biotin or SulfoTag

Drug : large molecule i.e. therapeutic antibody

- MW ADA ~ MW drug ~ 150 kDa
- Diversity of epitopes recognized by ADA
- Diversity of site for drug labeling without downgrading functionality





# Assay method for ADA detection directed against cytokines: new project for a clinical study

Three cytokines in human samples with LOW/MEDIUM risks of immunogenicity : CytA, CytB and CytC

Need to develop assay three methods for ADA detection


#### Difficulties related to cytokines :

- MW ADA ~ 150 kDa
- MW drug ~ 10-20 kDa
- Low number of epitopes recognized by ADA
- drug labeling risks to downgrade functionality
- Behavior of cytokines:


SANOFI 🎝

CytA : contains a membrane subunit

CytB: risk of aggregation or fixation to plasmatic protein CytC: is a heterodimer




# Assay method for ADA detection directed against cytokines: classical bridging format






## Assay method for ADA detection directed against cytokines: classical bridging format using Electrochimiluminescence (ECL)






# Method developments of ADA against cytokine using ECL



# Single Molecule Counting (SMC<sup>™</sup>) technology

Merck's propriety Single Molecule Counting (SMC<sup>™</sup>) technology :



Rotating objective moves laser spot at 50mm/sec through eluted analyte to scan.

Digital counting of molecules as they pass through interrogation space: Low level background "thresholded" out

A SMC<sup>™</sup> Immunogenicity Assay Development Kit (Cat. No. 03-0175-00) has been available since last year



- Signal output = Response signal
  - Need feedback for ADA

642 nm laser focused through plate

labeling with AlexaFluor 647

 Assessment of SMC<sup>™</sup> for development ADA methods for CytA, CytB and CytC using SMCxPro


Rotating objective scans laser spot through analyte.

Single fluorochromes excite and emit fluorescence :

**Expected benefit:** Decrease background and a sensitivity at 0.1 µg/mL

#### SANOFI 🎝

# Method development of ADA using SMC<sup>™</sup> technology




#### **Positive elements:**

- Capture with magnetic beads → best capture/presentation of epitope, washing efficiency
- Elution step → decrease non-specific signal
- SMC<sup>™</sup> is described as an ultrasensitive technology for PK and BM purpose, but there are no publications about ADA.

#### SANOFI 🌍


# Method developments of ADA against cytokine with SMC<sup>™</sup>



#### SANOFI 🌍

9

# Method developments of ADA against CytA with SMC<sup>™</sup>




#### SANOFI 🎝

# Method developments of ADA against CytA with SMC<sup>™</sup>

- Mix solution : 0.025 and 0.05 μg/mL
- Standard ADA : 0.1 to 100 µg/mL
- Matrix: diluent or plasma
- **MRD** : 1/60
- Final conditions :

MRD 1/60

Mix 0.025 µg/mL (labeled cytokines)



Low background noise signal


Sensitivity at 0.1 µg/mL

No instrument saturation for high concentrations of ADA

11

## Estimation of cutpoint with SMC™

For a first estimation of cut-point, 40 healthy plasmas were analyzed in screening condition MIX 0.025  $\mu$ g/mL and MRD 1/60



Estimation of Ncut-point at 1.34 and cut-point at 295 response signal (based on 95 percentile)

#### SANOFI 🎝

# Assessment of confirmation condition with SMC<sup>™</sup>

100000

- **Confirmation test** : competition with CytA at 1, 3 and 10 µg/mL
- Low PC : 0.1 µg/mL standard ADA
- **High PC** : 10 µg/mL standard ADA

3 and 10 µg/mL of CytA were sufficient to reach cut-point level

SANOFI 🎝

Be careful: too high CytA quantity could be unbalance the complex ADA-labeled cytokine and act as protein effect.

#### Pool Neg PC Neg 10000 LOW PC 0.1 μg/mL Signal HIGH PC 10 μg/mL 1000 96% % INHIBITION Response 99% 94% 95% 100 10 CytA 1µg/mL Control CytA 3µg/mL Confirmation condition Screening condition

CytA - SMC<sup>™</sup> - Confimation test (run11)

Cut-point

97%

Cyt A 10µg/mL

100%

# **Conclusions on these ADA methods**

- Only CytC ADA method could be developed with ECL (low background signal only for this cytokine)
- SMC<sup>™</sup> technology allows to decrease background signal and reach sensitivity at 0.1 µg/mL for CytA, CytB and CytC
- For CytA:
  - Experimental conditions optimized for screening and confirmation tests
  - Need to verify free drug tolerance, specificity and titration process
  - Next step : validation of method



# **Conclusions on SMC<sup>™</sup> technology**

SMC <sup>™</sup> is an alternative to other technologies for development of immunogenicity assay		
	Pros	Cons
SMC™ technology	Decrease background signal Increase sensitivity Magnetic beads allow to increase capture Reagents consumption can be reduced	require magnetic washer and robustness depends in part on the <b>wash step</b> optimization
<b>Productivity</b> (Number of samples per day for 1 equipment and 1 analyst)	around 40 samples / day more than 1 plate/day depending on magnetic washing equipment	
SMC™ Reagent	Immunogenicity Bead Based Assay Development Kit (967 €); possibility to buy buffers separately	
Robustness	yes but need to be validated for ADA method	
LIMS interface	yes	
IQ - OQ availability	yes	
Availability in CRO	not al	CRO
Multiplex		no
SANUFI		15

# THANK YOU

Acknowledgment: L. Diouloufet, P. Juhue, N. Bremond, L. Vermet, O. Fedeli Sanofi Montpellier, France

#### And

Ludivine Grosjean , Daniel Garcia West Merck KGaA Darmstadt, Germany

